The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study

Abstract Background Disitamab vedotin (DV, RC48-ADC) has shown promising efficacy and manageable safety as monotherapy or combined with immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) patients progressing after systemic chemotherapy. This study evaluates the efficacy and...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Cheoklong Ng, Taile Jing, Shicheng Yu, Jianjun Ye, Shun Zhang, Zhankui Jia, Qi Tang, Xiaoyi Hu, Minfeng Chen, Weiping Huang, Jitao Wu, Hai Bi, Zejun Yan, Haibo Shen, Wei Xiong, Zheng Liu, Jun Xiao, Tao Zhang, Xuedong Wei, Hailong Hu, Qing Yang, Yichu Yuan, Zhiyang Huang, Wei Xue, Yige Bao, Guoqing Ding, Dan Xia, Jiwei Huang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Springer 2025-09-01
Serie:	Cancer Immunology, Immunotherapy
Soggetti:	Disitamab vedotin Immune checkpoint inhibitors Upper tract urothelial carcinoma Targeted therapy Immunotherapy
Accesso online:	https://doi.org/10.1007/s00262-025-04154-5
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!